Dideoxynucleosides

"Dideoxynucleosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription.

Descriptor ID	D015224
MeSH Number(s)	D13.570.230.500
Concept/Terms	Dideoxynucleosides Dideoxynucleosides ddNus 2',3'-Dideoxynucleosides 2',3'-Dideoxynucleosides 2',3' Dideoxynucleosides Dideoxyribonucleosides Dideoxyribonucleosides

Below are MeSH descriptors whose meaning is more general than "Dideoxynucleosides".

Chemicals and Drugs [D]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleosides [D13.570]
Deoxyribonucleosides [D13.570.230]
Dideoxynucleosides [D13.570.230.500]

Below are MeSH descriptors whose meaning is related to "Dideoxynucleosides".

Below are MeSH descriptors whose meaning is more specific than "Dideoxynucleosides".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dideoxynucleosides" by people in this website by year, and whether "Dideoxynucleosides" was a major or minor topic of these publications.

Bar chart showing 9 publications over 8 distinct years, with a maximum of 2 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2003	1	0	1
2007	0	1	1
2008	2	0	2
2009	1	0	1
2010	1	0	1
2016	0	1	1
2020	0	1	1

Below are the most recent publications written about "Dideoxynucleosides" by people in Profiles.

Zeinert RD, Baniasadi H, Tu BP, Chien P. The Lon Protease Links Nucleotide Metabolism with Proteotoxic Stress. Mol Cell. 2020 09 03; 79(5):758-767.e6.

View in: PubMed
Bolduc P, Roder N, Colgate E, Cheeseman SH. Care of Patients With HIV Infection: Antiretroviral Drug Regimens. FP Essent. 2016 Apr; 443:23-30.

View in: PubMed
Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010 Oct 15; 51(8):963-72.

View in: PubMed
Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009 May 01; 51(1):20-8.

View in: PubMed
Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2008 Apr-Jun; 7(2):121-9.

View in: PubMed
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, J?gel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 07; 358(6):568-79.

View in: PubMed
Jacobs AH, Rueger MA, Winkeler A, Li H, Vollmar S, Waerzeggers Y, Rueckriem B, Kummer C, Dittmar C, Klein M, Heneka MT, Herrlinger U, Fraefel C, Graf R, Wienhard K, Heiss WD. Imaging-guided gene therapy of experimental gliomas. Cancer Res. 2007 Feb 15; 67(4):1706-15.

View in: PubMed
Keiser P, Nassar N, Skiest D, Andrews C, Yazdani B, White A, Hetherington S. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. Int J STD AIDS. 2003 Jul; 14(7):478-81.

View in: PubMed
Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, Back D. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):45-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals